FGFR1 - Wiki-MPM

Novel	Interactant Symbol	Name	Associated Pathways Hide	Binding Drugs Hide	Associated Diseases Hide
Novel	PPP2CB	protein phosphatase 2 catalytic subunit beta	Inhibition of replication initiation of damaged DNA by RB1/E2F1 Spry regulation of FGF signaling Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal Integration of energy metabolism PP2A-mediated dephosphorylation of key metabolic factors DARPP-32 events Degradation of beta-catenin by the destruction complex Beta-catenin phosphorylation cascade ERK/MAPK targets ERKs are inactivated MASTL Facilitates Mitotic Progression Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion CTLA4 inhibitory signaling Platelet sensitization by LDL Disassembly of the destruction complex and recruitment of AXIN to the membrane Disassembly of the destruction complex and recruitment of AXIN to the membrane Signaling by GSK3beta mutants S33 mutants of beta-catenin aren't phosphorylated S37 mutants of beta-catenin aren't phosphorylated S45 mutants of beta-catenin aren't phosphorylated T41 mutants of beta-catenin aren't phosphorylated APC truncation mutants have impaired AXIN binding AXIN missense mutants destabilize the destruction complex Truncations of AMER1 destabilize the destruction complex RHO GTPases Activate Formins RAF activation Negative regulation of MAPK pathway Regulation of TP53 Degradation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Mitotic Prometaphase Cyclin D associated events in G1 Cyclin A/B1/B2 associated events during G2/M transition Regulation of glycolysis by fructose 2,6-bisphosphate metabolism EML4 and NUDC in mitotic spindle formation	Vitamin E
Novel	TPMT	thiopurine S-methyltransferase	Methylation Defective TPMT causes Thiopurine S-methyltransferase deficiency (TPMT deficiency)	Olsalazine	Thiopurine S-methyltransferase deficiency (TPMT deficiency)
Novel	EIF4EBP1	eukaryotic translation initiation factor 4E binding protein 1	mTORC1-mediated signalling Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S
Novel	NRG1	neuregulin 1	Signaling by ERBB2 Signaling by ERBB4 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PI3K events in ERBB4 signaling SHC1 events in ERBB4 signaling Nuclear signaling by ERBB4 PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling Long-term potentiation Signaling by ERBB2 KD Mutants Signaling by ERBB2 TMD/JMD mutants
Novel	OR51B4	olfactory receptor family 51 subfamily B member 4	Olfactory Signaling Pathway
Novel	SHB	SH2 domain containing adaptor protein B	VEGFA-VEGFR2 Pathway VEGFA-VEGFR2 Pathway
Novel	ZFYVE1	zinc finger FYVE-type containing 1
	HTR1A	5-hydroxytryptamine receptor 1A	Serotonin receptors	Eletriptan Ziprasidone Methysergide Cabergoline Zolmitriptan Amitriptyline Olanzapine Clozapine Loxapine Pramipexole Methylphenidate Imipramine Chlorpromazine Buspirone Haloperidol Nortriptyline Amoxapine Propranolol Fenfluramine Lisuride Trazodone Sumatriptan Ergotamine Apomorphine Paroxetine Trimipramine Risperidone Alprenolol Ondansetron Naratriptan Pindolol Dopamine Ergoloid mesylate Doxepin Nefazodone Desipramine Escitalopram Pergolide Bromocriptine Ketamine Quetiapine Aripiprazole Chlorprothixene Paliperidone Penbutolol Yohimbine Acepromazine Alverine Molindone Pipotiazine Thioproperazine Lysergic acid diethylamide Dapoxetine Bifeprunox Flibanserin Iloperidone Lofexidine Lesopitron Rotigotine MN-305 LI-301 Naluzotan Cariprazine Mianserin Pizotifen Asenapine Xaliproden Dotarizine Sarizotan Repinotan Robalzotan Vilazodone Bopindolol Cinitapride Lurasidone Perospirone Cannabidiol Vortioxetine Brexpiprazole Dosulepin Pirlindole Tianeptine Setiptiline Dihydroergocornine Tetrahydrocannabivarin Pardoprunox Gilteritinib Tiapride Dihydroergocristine Medical Cannabis 5-methoxy-N,N-dimethyltryptamine Nabiximols Aripiprazole lauroxil SEP-363856
	PTPN1	protein tyrosine phosphatase non-receptor type 1	Integrin signaling Negative regulation of MET activity Regulation of IFNG signaling PTK6 Down-Regulation MECP2 regulates neuronal receptors and channels Regulation of IFNA signaling Growth hormone receptor signaling Growth hormone receptor signaling	3-(Oxalyl-Amino)-Naphthalene-2-Carboxylic Acid 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid 5-(2-Fluoro-5-{(1E)-3-[3-hydroxy-2-(methoxycarbonyl)phenoxy]-1-propen-1-yl}phenyl)-1,2-oxazole-3-carboxylic acid 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Thiopyran-3-Carboxylic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid (4-Sulfamoyl-Phenyl)-Amide [[4-(Aminomethyl)Phenyl]Amino]Oxo-Acetic Acid, {4-[(2S)-2-({[(1S)-1-Carboxy-2-phenylethyl]carbamoyl}amino)-3-oxo-3-(pentylamino)propyl]phenoxy}malonic acid Compound 19 3-(4-{2-[2-(2-bromo-acetylamino)-ethyldisulfanyl]-ethylcarbamoyl}-cyclohexylcarbamoyl)-pyrazine-2-carboxylic acid 2-(Oxalyl-Amino)-Benzoic Acid {[2-(1h-1,2,3-Benzotriazol-1-Yl)-2-(3,4-Difluorophenyl)Propane-1,3-Diyl]Bis[4,1-Phenylene(Difluoromethylene)]}Bis(Phosphonic Acid) Novo Nordisk a/S Compound N-(Bromoacetyl)-beta-alanyl-N-(2-{4-[(carboxycarbonyl)amino]phenyl}ethyl)-L-serinamide 7-(1,1-Dioxo-1h-Benzo[D]Isothiazol-3-Yloxymethyl)-2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid PNU177836 2-(Oxalyl-Amino)-4,7-Dihydro-5h-Thieno[2,3-C]Pyran-3-Carboxylic Acid {[7-(Difluoro-Phosphono-Methyl)-Naphthalen-2-Yl]-Difluoro-Methyl}-Phosphonic Acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid [4-(Thiazol-2-Ylsulfamoyl)-Phenyl]-Amide (4S)-5-[[(2S)-1-[[(2S)-1-Amino-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-4-benzamido-5-oxopentanoic acid 4-[[(2S)-1-[[6-[(1-Amino-1-oxo-3-sulfanylpropan-2-yl)amino]-6-oxohexyl]amino]-3-[4-[difluoro(phosphono)methyl]phenyl]-1-oxopropan-2-yl]amino]-3-[[2-[4-[difluoro(phosphono)methyl]phenyl]acetyl]amino]-4-oxobutanoic acid L-cysteic acid 2-(Oxalyl-Amino)-4,5,6,7-Tetrahydro-Thieno[2,3-C]Pyridine-3-Carboxylic Acid 4-Carbamoyl-4-{[6-(Difluoro-Phosphono-Methyl)-Naphthalene-2-Carbonyl]-Amino}-Butyric Acid Compound 5, 2-(Naphthalen-1-Yl-Oxalyl-Amino)-Benzoicacid 6-(Oxalyl-Amino)-1h-Indole-5-Carboxylic Acid 2-[{4-[(2S)-2-{[(Allyloxy)carbonyl]amino}-3-({4-[3-hydroxy-2-(methoxycarbonyl)phenoxy]butyl}amino)-3-oxopropyl]phenyl}(carboxycarbonyl)amino]benzoic acid 3-(3,5-Dibromo-4-Hydroxy-Benzoyl)-2-Ethyl-Benzofuran-6-Sulfonic Acid Dimethylamide [(4-{4-[4-(Difluoro-Phosphono-Methyl)-Phenyl]-Butyl}-Phenyl)-Difluoro-Methyl]-Phosphonic Acid {4-[(2s,4e)-2-(1,3-Benzothiazol-2-Yl)-2-(1h-1,2,3-Benzotriazol-1-Yl)-5-Phenylpent-4-Enyl]Phenyl}(Difluoro)Methylphosphonic Acid N-(3-Carboxypropanoyl)-L-phenylalanyl-3-carboxy-O-(carboxymethyl)-N-pentyl-L-tyrosinamide 1-METHYL-3-PHENYL-1H-PYRAZOL-5-YLSULFAMIC ACID ISIS 113715 Trodusquemine Ertiprotafib 4-BROMO-3-(CARBOXYMETHOXY)-5-[3-(CYCLOHEXYLAMINO)PHENYL]THIOPHENE-2-CARBOXYLIC ACID [(3S)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 4-BROMO-3-(CARBOXYMETHOXY)-5-PHENYLTHIOPHENE-2-CARBOXYLIC ACID 5-(4-CHLORO-5-PHENYL-3-THIENYL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 4-BROMO-3-(CARBOXYMETHOXY)-5-(4-HYDROXYPHENYL)THIOPHENE-2-CARBOXYLIC ACID [{2-bromo-4-[(2R)-3-oxo-2,3-diphenylpropyl]phenyl}(difluoro)methyl]phosphonic acid 5-[3-(BENZYLAMINO)PHENYL]-4-BROMO-3-(CARBOXYMETHOXY)THIOPHENE-2-CARBOXYLIC ACID 2-[(7-HYDROXY-NAPHTHALEN-1-YL)-OXALYL-AMINO]-BENZOIC ACID 3-(CARBOXYMETHOXY)THIENO[2,3-B]PYRIDINE-2-CARBOXYLIC ACID 4-PHOSPHONOOXY-PHENYL-METHYL-[4-PHOSPHONOOXY]BENZEN N-ACETYL-L-PHENYLALANYL-4-[DIFLUORO(PHOSPHONO)METHYL]-L-PHENYLALANINAMIDE [(3R)-3-(Methylcarbamoyl)-2-{[(2-methyl-2-propanyl)oxy]carbonyl}-1,2,3,4-tetrahydro-7-isoquinolinyl]sulfamic acid 5-(3-HYDROXYPHENYL)ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDE 5-(3-{3-[3-HYDROXY-2-(METHOXYCARBONYL)PHENOXY]PROPENYL}PHENYL)-4-(HYDROXYMETHYL)ISOXAZOLE-3-CARBOXYLIC ACID ISOTHIAZOLIDINONE ANALOG 4-[3-(dibenzylamino)phenyl]-2,4-dioxobutanoic acid p-Benzoyl-L-phenylalanine 6-(DIFLUORO-PHOSPHONO-METHYL)-NAPHTHALENE-2-CARBOXYLIC ACID (3R)-METHYLCARBAMOYL-7-SULFOAMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID BENZYL ESTER 5-(4-METHOXYBIPHENYL-3-YL)-1,2,5-THIADIAZOLIDIN-3-ONE 1,1-DIOXIDE 1,2,5-THIADIAZOLIDIN-3-ONE-1,1-DIOXIDE (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid
	PDGFRB	platelet derived growth factor receptor beta	PIP3 activates AKT signaling Downstream signal transduction Signaling by PDGF Constitutive Signaling by Aberrant PI3K in Cancer RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	Becaplermin Sorafenib Imatinib Dasatinib Sunitinib XL999 XL820 Pazopanib Midostaurin Regorafenib Nintedanib Polaprezinc Trapidil Foreskin fibroblast (neonatal) Fostamatinib Erdafitinib Pexidartinib Ripretinib Pralsetinib	Glioma
	ERBB2	erb-b2 receptor tyrosine kinase 2	Signaling by ERBB2 SHC1 events in ERBB2 signaling SHC1 events in ERBB2 signaling PLCG1 events in ERBB2 signaling PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Downregulation of ERBB2:ERBB3 signaling GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D induced cell migration and growth-cone collapse RAF/MAP kinase cascade ERBB2 Regulates Cell Motility PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ERBB2 Activates PTK6 Signaling Downregulation of ERBB2 signaling TFAP2 (AP-2) family regulates transcription of growth factors and their receptors Constitutive Signaling by Overexpressed ERBB2 Drug-mediated inhibition of ERBB2 signaling Signaling by ERBB2 KD Mutants Resistance of ERBB2 KD mutants to trastuzumab Resistance of ERBB2 KD mutants to sapitinib Resistance of ERBB2 KD mutants to tesevatinib Resistance of ERBB2 KD mutants to neratinib Resistance of ERBB2 KD mutants to osimertinib Resistance of ERBB2 KD mutants to afatinib Resistance of ERBB2 KD mutants to AEE788 Resistance of ERBB2 KD mutants to lapatinib Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Drug resistance in ERBB2 TMD/JMD mutants	Trastuzumab Lapatinib IGN311 Trastuzumab emtansine Varlitinib AV-412 Pertuzumab Afatinib Tucatinib Tesevatinib Fostamatinib Brigatinib Margetuximab Zanubrutinib	Choriocarcinoma Pancreatic cancer Gastric cancer Bladder cancer Endometrial Cancer Ovarian cancer Cholangiocarcinoma Breast cancer Cervical cancer
	FDPS	farnesyl diphosphate synthase	Cholesterol biosynthesis Activation of gene expression by SREBF (SREBP)	Pamidronic acid Zoledronic acid Alendronic acid Ibandronate Risedronic acid Dimethylallyl Diphosphate Isopentyl Pyrophosphate Geranyl Diphosphate ISOPENTENYL PYROPHOSPHATE Incadronic acid Minodronic acid Farnesyl diphosphate Geranylgeranyl diphosphate
	FGF1	fibroblast growth factor 1	PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR1b ligand binding and activation FGFR3b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR2b ligand binding and activation FGFR3 mutant receptor activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease RAF/MAP kinase cascade PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR2 IIIa TM Signaling by FGFR3 point mutants in cancer	Pentosan polysulfate Amlexanox Heparin Sucrosofate Formic acid O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine Naphthalene Trisulfonate Pazopanib 5-aminonaphthalene-2-sulfonic acid Foreskin fibroblast (neonatal) Foreskin keratinocyte (neonatal)
	ITGB3	integrin subunit beta 3	Platelet degranulation Elastic fibre formation PECAM1 interactions Molecules associated with elastic fibres Integrin cell surface interactions Integrin cell surface interactions Syndecan interactions Syndecan interactions ECM proteoglycans Integrin signaling GRB2:SOS provides linkage to MAPK signaling for Integrins p130Cas linkage to MAPK signaling for integrins VEGFA-VEGFR2 Pathway Signal transduction by L1 MAP2K and MAPK activation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants	Abciximab Eptifibatide Antithymocyte immunoglobulin (rabbit) Levothyroxine Tirofiban Resveratrol Lefradafiban LM-609 Fradafiban Ferric maltol	Glanzmann thrombasthenia Allograft rejection
	RARA	retinoic acid receptor alpha	Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Signaling by Retinoic Acid Activation of anterior HOX genes in hindbrain development during early embryogenesis Transcriptional regulation of granulopoiesis Transcriptional regulation of granulopoiesis	Adapalene Acitretin Alitretinoin Tretinoin Tazarotene Etretinate Isotretinoin Tamibarotene LGD-1550 Trifarotene	Isolated orofacial clefts, including: Cleft lip with or without cleft palate; Cleft palate Acute myeloid leukemia (AML)
	FGF2	fibroblast growth factor 2	PI3K Cascade PIP3 activates AKT signaling Signaling by activated point mutants of FGFR1 Signaling by activated point mutants of FGFR3 FGFR4 ligand binding and activation FGFR1b ligand binding and activation FGFR3c ligand binding and activation FGFR1c ligand binding and activation FGFR2c ligand binding and activation FGFR2b ligand binding and activation FGFR3 mutant receptor activation Activated point mutants of FGFR2 Constitutive Signaling by Aberrant PI3K in Cancer POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation Syndecan interactions Non-integrin membrane-ECM interactions Phospholipase C-mediated cascade: FGFR1 Phospholipase C-mediated cascade; FGFR2 Phospholipase C-mediated cascade; FGFR3 Phospholipase C-mediated cascade; FGFR4 Downstream signaling of activated FGFR1 SHC-mediated cascade:FGFR1 PI-3K cascade:FGFR1 FRS-mediated FGFR1 signaling PI-3K cascade:FGFR2 SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling PI-3K cascade:FGFR3 FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 PI-3K cascade:FGFR4 Negative regulation of FGFR1 signaling Negative regulation of FGFR2 signaling Negative regulation of FGFR3 signaling Negative regulation of FGFR4 signaling Signaling by FGFR2 in disease Signaling by FGFR1 in disease FGFRL1 modulation of FGFR1 signaling RAF/MAP kinase cascade Interleukin-4 and Interleukin-13 signaling PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling Signaling by FGFR2 IIIa TM Signaling by FGFR3 point mutants in cancer	Sucralfate Pentosan polysulfate Sirolimus Heparin 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid N,O6-Disulfo-Glucosamine 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid ABT-510
	PKM	pyruvate kinase M1/2	Neutrophil degranulation	Pyruvic acid L-Phospholactate 2-Phosphoglycolic Acid 6-(2-fluorobenzyl)-2,4-dimethyl-4,6-dihydro-5H-thieno[2',3':4,5]pyrrolo[2,3-d]pyridazin-5-one 1-[(2,6-difluorophenyl)sulfonyl]-4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)piperazine 1-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-4-[(4-methoxyphenyl)sulfonyl]piperazine Copper Artenimol
	LDHA	lactate dehydrogenase A	Pyruvate metabolism	NADH Etheno-NAD Nicotinamide Oxamic Acid Stiripentol Copper Artenimol
	MMP2	matrix metallopeptidase 2	Collagen degradation Collagen degradation Degradation of the extracellular matrix Degradation of the extracellular matrix Activation of Matrix Metalloproteinases Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) EPH-ephrin mediated repulsion of cells Interleukin-4 and Interleukin-13 signaling Extra-nuclear estrogen signaling	Marimastat Captopril SC-74020 Halofuginone AE-941 Endostatin	Choriocarcinoma Penile cancer Torg-Winchester syndrome
	ITK	IL2 inducible T cell kinase	Generation of second messenger molecules FCERI mediated Ca+2 mobilization FCERI mediated Ca+2 mobilization	Staurosporine Pazopanib Fostamatinib Zanubrutinib

Search Results for: FGFR1